Down-regulation of NR4A1 in follicular thyroid carcinomas is restored following lithium treatment
Cléber P. Camacho
Genetic Bases of Thyroid Tumors Laboratory, Division of Genetics, Department of Morphology
Laboratory of Molecular Endocrinology, Division of Endocrinology, Department of Medicine
Search for more papers by this authorFlavia R. M. Latini
Genetic Bases of Thyroid Tumors Laboratory, Division of Genetics, Department of Morphology
Laboratory of Molecular Endocrinology, Division of Endocrinology, Department of Medicine
Search for more papers by this authorGisele Oler
Genetic Bases of Thyroid Tumors Laboratory, Division of Genetics, Department of Morphology
Laboratory of Molecular Endocrinology, Division of Endocrinology, Department of Medicine
Search for more papers by this authorFlavio C. Hojaij
Division of Head and Neck Surgery, Federal University of São Paulo, São Paulo, Brazil
Search for more papers by this authorRui M. B. Maciel
Laboratory of Molecular Endocrinology, Division of Endocrinology, Department of Medicine
Search for more papers by this authorGregory J. Riggins
Department of Neurosurgery, Johns Hopkins University Medical School, Baltimore, Maryland, USA
Search for more papers by this authorJanete M. Cerutti
Genetic Bases of Thyroid Tumors Laboratory, Division of Genetics, Department of Morphology
Laboratory of Molecular Endocrinology, Division of Endocrinology, Department of Medicine
Search for more papers by this authorCléber P. Camacho
Genetic Bases of Thyroid Tumors Laboratory, Division of Genetics, Department of Morphology
Laboratory of Molecular Endocrinology, Division of Endocrinology, Department of Medicine
Search for more papers by this authorFlavia R. M. Latini
Genetic Bases of Thyroid Tumors Laboratory, Division of Genetics, Department of Morphology
Laboratory of Molecular Endocrinology, Division of Endocrinology, Department of Medicine
Search for more papers by this authorGisele Oler
Genetic Bases of Thyroid Tumors Laboratory, Division of Genetics, Department of Morphology
Laboratory of Molecular Endocrinology, Division of Endocrinology, Department of Medicine
Search for more papers by this authorFlavio C. Hojaij
Division of Head and Neck Surgery, Federal University of São Paulo, São Paulo, Brazil
Search for more papers by this authorRui M. B. Maciel
Laboratory of Molecular Endocrinology, Division of Endocrinology, Department of Medicine
Search for more papers by this authorGregory J. Riggins
Department of Neurosurgery, Johns Hopkins University Medical School, Baltimore, Maryland, USA
Search for more papers by this authorJanete M. Cerutti
Genetic Bases of Thyroid Tumors Laboratory, Division of Genetics, Department of Morphology
Laboratory of Molecular Endocrinology, Division of Endocrinology, Department of Medicine
Search for more papers by this authorSummary
Introduction The identification of follicular thyroid adenoma-associated transcripts will lead to a better understanding of the events involved in pathogenesis and progression of follicular tumours. Using Serial Analysis of Gene Expression, we identified five genes that are absent in a malignant follicular thyroid carcinoma (FTC) library, but expressed in follicular adenoma (FTA) and normal thyroid libraries.
Methods NR4A1, one of the five genes, was validated in a set of 27 normal thyroid tissues, 10 FTAs and 14 FTCs and three thyroid carcinoma cell lines by real time PCR. NR4A1 can be transiently increased by a variety of stimuli, including lithium, which is used as adjuvant therapy of thyroid carcinoma with 131I. We tested if lithium could restore NR4A1 expression. The expression of other genes potentially involved in the same signalling pathway was tested. To this end, lithium was used at different concentration (10 mm or 20 mm) and time (2 h and 24 h) and the level of expression was tested by quantitative PCR. We next tested if Lithium could affect cell growth and apoptosis.
Results We observed that NR4A1 expression was under-expressed in most of the FTCs investigated, compared with expression in normal thyroid tissues and FTAs. We also found a positive correlation between NR4A1 and FOSB gene expression. Lithium induced NR4A1 and FOSB expression, reduced CCDN1 expression, inhibited cell growth and triggered apoptosis in a FTC cell line.
Conclusions NR4A1 is under-expressed in most of FTCs. The loss of expression of both NR4A1 and the Wnt pathway gene FOSB was correlated with malignancy. This is consistent with the hypothesis that its loss of expression is part of the transformation process of FTCs, either as a direct or indirect consequence of Wnt pathway alterations. Lithium restores NR4A1 expression, induces apoptosis and reduces cell growth. These findings may explain a possible molecular mechanism of lithium's therapeutic action.
References
- 1 Davies, L. & Welch, H.G. (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. The Journal of the American Medical Association, 295, 2164–2167.
- 2 Kimura, E.T., Nikiforova, M.N., Zhu, Z. et al. (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Research, 63, 1454–1457.
- 3 Viglietto, G., Chiappetta, G., Martinez-Tello, F.J. et al. (1995) RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene, 11, 1207–1210.
- 4 Soares, P., Trovisco, V., Rocha, A.S. et al. (2003) BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene, 22, 4578–4580.
- 5 Marques, A.R., Espadinha, C., Catarino, A.L. et al. (2002) Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. Journal of Clinical Endocrinology and Metabolism, 87, 3947–3952.
- 6 Cheung, L., Messina, M., Gill, A. et al. (2003) Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. Journal of Clinical Endocrinology and Metabolism, 88, 354–357.
- 7 Nakabashi, C.C., Guimaraes, G.S., Michaluart, P. Jr et al. (2004) The expression of PAX8-PPARgamma rearrangements is not specific to follicular thyroid carcinoma. Clinical Endocrinology, 61, 280–282.
- 8 Nikiforova, M.N., Lynch, R.A., Biddinger, P.W. et al. (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. Journal of Clinical Endocrinology and Metabolism, 88, 2318–2326.
- 9 Kroll, T.G., Sarraf, P., Pecciarini, L. et al. (2000) PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science, 289, 1357–1360.
- 10 Cheng, G., Lewis, A.E. & Meinkoth, J.L. (2003) Ras stimulates aberrant cell cycle progression and apoptosis in rat thyroid cells. Molecular Endocrinology, 17, 450–459.
- 11 Nikiforova, M.N., Biddinger, P.W., Caudill, C.M. et al. (2002) PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. American Journal of Surgery Pathology, 26, 1016–1023.
- 12 Cerutti, J.M., Delcelo, R., Amadei, M.J. et al. (2004) A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. Journal of Clinical Investigation, 113, 1234–1242.
- 13 Cerutti, J.M., Latini, F.R., Nakabashi, C. et al. (2006) Diagnosis of suspicious thyroid nodules using four protein biomarkers. Clinical Cancer Research, 12, 3311–3318.
- 14 Aranda, A. & Pascual, A. (2001) Nuclear hormone receptors and gene expression. Physiological Reviews, 81, 1269–1304.
- 15 Wu, Q., Liu, S., Ye, X.F. et al. (2002) Dual roles of Nur77 in selective regulation of apoptosis and cell cycle by TPA and ATRA in gastric cancer cells. Carcinogenesis, 23, 1583–1592.
- 16 Chtarbova, S., Nimmrich, I., Erdmann, S. et al. (2002) Murine Nr4a1 and Herpud1 are up-regulated by Wnt-1, but the homologous human genes are independent from beta-catenin activation. The Biochemical Journal, 367, 723–728.
- 17 Weih, F., Ryseck, R.P., Chen, L. et al. (1996) Apoptosis of nur77/N10-transgenic thymocytes involves the Fas/Fas ligand pathway. Proceedings of the National Academy of Sciences of the USA, 93, 5533–5538.
- 18 Chintharlapalli, S., Burghardt, R., Papineni, S. et al. (2005) Activation of Nur77 by selected 1,1-Bis (3′-indolyl) -1-(, p. -substituted phenyl) methanes induces apoptosis through nuclear pathways. Journal of Biological Chemistry, 280, 24903–24914.
- 19 Maxwell, M.A. & Muscat, G.E. (2006) The NR4A subgroup: immediate early response genes with pleiotropic physiological roles. Nuclear Receptor Signaling, 4, 1–8.
- 20 Briere, J., Pousset, G., Darsy, P. et al. (1974) The advantage of lithium in association with iodine 131 in the treatement of functioning metastasis of the thyroid cancer. Annales D’endocrinologie, 35, 281–282.
- 21 Koong, S.S., Reynolds, J.C., Movius, E.G. et al. (1999) Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 84, 912–916.
- 22 Van Staveren, W.C., Solis, D.W., Delys, L. et al. (2007) Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype. Cancer Research, 67, 8113–8120.
- 23 Matsuo, K., Tang, S.H., Sharifi, B. et al. (1993) Growth factor production by human thyroid carcinoma cells: abundant expression of a platelet-derived growth factor-B-like protein by a human papillary carcinoma cell line. Journal of Clinical Endocrinology and Metabolism, 77, 996–1004.
- 24 Estour, B., Van Herle, A.J., Juillard, G.J. et al. (1989) Characterization of a human follicular thyroid carcinoma cell line (UCLA RO 82 W-1). Virchows Archiv B, Cell Pathology Including Molecular Pathology, 57, 167–174.
- 25 De Nigris, F., Cerutti, J., Morelli, C. et al. (2002) Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues. British Journal of Cancer, 86, 917–923.
- 26 Arnaldi, L.A., Borra, R.C., Maciel, R.M. et al. (2005) Gene expression profiles reveal that DCN, DIO1, and DIO2 are underexpressed in benign and malignant thyroid tumors. Thyroid, 15, 210–221.
- 27 Cerutti, J.M., Ebina, K.N., Matsuo, S.E. et al. (2003) Expression of Smad4 and Smad7 in human thyroid follicular carcinoma cell lines. Journal of Endocrinological Investigation, 26, 516–521.
- 28 Cerutti, J.M., Oler, G., Michaluart, P. Jr et al. (2007) Molecular profiling of matched samples identifies biomarkers of papillary thyroid carcinoma lymph node metastasis. Cancer Research, 67, 7885–7892.
- 29 Rao, A.S., Kremenevskaja, N., Resch, J. et al. (2005) Lithium stimulates proliferation in cultured thyrocytes by activating Wnt/beta-catenin signalling. European Journal of Endocrinology, 153, 929–938.
- 30 Latini, F., Hemerly, J., Oler, G. et al. (2008) Re-expression of ABI3 BP suppresses thyroid tumor growth by promoting senescence and inhibiting invasion. Endocrine-Related Cancer, 15, 787–799.
- 31 Boon, K., Osorio, E.C., Greenhut, S.F. et al. (2002) An anatomy of normal and malignant gene expression. Proceedings of the National Academy of Sciences of the USA, 99, 11287–11292.
- 32 Mao, C.D., Hoang, P. & DiCorleto, P.E. (2001) Lithium inhibits cell cycle progression and induces stabilization of p53 in bovine aortic endothelial cells. Journal of Biological Chemistry, 276, 26180–26188.
- 33 Li, Y., Lin, B., Agadir, A. et al. (1998) Molecular determinants of AHPN (CD437) -induced growth arrest and apoptosis in human lung cancer cell lines. Molecular and Cellular Biology, 18, 4719–4731.
- 34 Woronicz, J.D., Calnan, B., Ngo, V. et al. (1994) Requirement for the orphan steroid receptor Nur77 in apoptosis of T-cell hybridomas. Nature, 367, 277–281.
- 35 Pekarsky, Y., Hallas, C., Palamarchuk, A. et al. (2001) Akt phosphorylates and regulates the orphan nuclear receptor Nur77. Proceedings of the National Academy of Sciences of the USA, 98, 3690–3694.
- 36 Fujii, Y., Matsuda, S., Takayama, G. et al. (2008) ERK5 is involved in TCR-induced apoptosis through the modification of Nur77. Genes to Cells, 13, 411–419.
- 37 Li, H., Kolluri, S.K., Gu, J. et al. (2000) Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science, 289, 1159–1164.
- 38 Lin, B., Kolluri, S.K., Lin, F. et al. (2004) Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell, 116, 527–540.
- 39 Mullican, S.E., Zhang, S., Konopleva, M. et al. (2007) Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nature Medicine, 13, 730–735.
- 40 Hazel, T.G., Nathans, D. & Lau, L.F. (1988) A gene inducible by serum growth factors encodes a member of the steroid and thyroid hormone receptor superfamily. Proceedings of the National Academy of Sciences of the USA, 85, 8444–8448.
- 41 Schou, M., Amdisen, A., Eskjaer Jensen, S. et al. (1968) Occurrence of goitre during lithium treatment. British Medical Journal, 3, 710–713.
- 42 Temple, R., Berman, M., Robbins, J. et al. (1972) The use of lithium in the treatment of thyrotoxicosis. Journal of Clinical Investigation, 51, 2746–2756.
- 43 Pacini, F., Schlumberger, M., Dralle, H. et al. (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology, 154, 787–803.
- 44 Cooper, D.S., Doherty, G.M., Haugen, B.R. et al. (2006) Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 16, 109–142.
- 45 Sibayama-Imazu, T., Fujisawa, Y., Masuda, Y. et al. (2008) Induction of apoptosis in PA-1 ovarian cancer cells by vitamin K (2) is associated with an increase in the level of TR3/Nur77 and its accumulation in mitochondria and nuclei. Journal of Cancer Research Clinical Oncology, 134, 803–812.
- 46 Stambolic, V., Ruel, L. & Woodgett, J.R. (1996) Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Current Biology, 6, 1664–1668.
- 47 Kappes, A., Vaccaro, A., Kunnimalaiyaan, M. et al. (2007) Lithium ions: a novel treatment for pheochromocytomas and paragangliomas. Surgery, 141, 161–165.
- 48 Kunnimalaiyaan, M., Vaccaro, A.M., Ndiaye, M.A. et al. (2007) Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Molecular Cancer Therapy, 6, 1151–1158.
- 49 Giles, R.H., Van Es, J.H. & Clevers, H. (2003) Caught up in a Wnt storm: Wnt signaling in cancer. Biochemica Biophysica Acta, 1653, 1–24.
- 50 Penso, J. & Beitner, R. (2003) Lithium detaches hexokinase from mitochondria and inhibits proliferation of B16 melanoma cells. Molecular Genetics and Metabolism, 78, 74–78.
- 51 Karlovic, D., Jakopec, S., Dubravcic, K. et al. (2007) Lithium increases expression of p21 (WAF/Cip1) and survivin in human glioblastoma cells. Cell Biology and Toxicology, 23, 83–90.
- 52 Tetsu, O. & McCormick, F. (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature, 398, 422–426.
- 53 Tice, D.A., Soloviev, I. & Polakis, P. (2002) Activation of the Wnt pathway interferes with serum response element-driven transcription of immediate early genes. Journal of Biological Chemistry, 277, 6118–6123.
- 54 Meirmanov, S., Nakashima, M., Kondo, H. et al. (2003) Correlation of cytoplasmic beta-catenin and cyclin D1 overexpression during thyroid carcinogenesis around Semipalatinsk nuclear test site. Thyroid, 13, 537–545.
- 55 Huang, Y., Prasad, M., Lemon, W.J. et al. (2001) Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proceedings of the National Academy of Sciences of the USA, 98, 15044–15049.
- 56 Melillo, R.M., Castellone, M.D., Guarino, V. et al. (2005) The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation, 115, 1068–1081.
- 57 Puxeddu, E., Moretti, S., Giannico, A. et al. (2003) Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas. European Journal of Endocrinology, 148, 505–513.
Citing Literature
